Q&A

Transdermal progesterone ineffective for menopausal symptoms

J Fam Pract. 2003 May;52(5):349-364
By
Deborah Sturpe, PharmD, BCPS
Author and Disclosure Information

  • BACKGROUND: Natural progesterone is touted as treatment for the vasomotor, mood, and sexual disturbances associated with menopause. No well-designed clinical trials have assessed this claim. This study evaluates the effectiveness of transdermal progesterone cream in the treatment of menopausal symptoms.
  • POPULATION STUDIED: Investigators recruited 80 study participants from the Sydney Menopause Centre at the Royal Hospital for Women in Australia. Postmenopausal women aged 45 to 70 years were eligible if they suffered at least 1 hot flush daily and had not used drugs or herbs for hot flushes within 8 weeks of study enrollment. The average age of study participants was 54 years, and median time since menopause was 3.2 years.
  • STUDY DESIGN AND VALIDITY: In this randomized, blinded study, participants used progesterone cream 32 mg or matching placebo daily for 12 weeks. The progesterone cream used in the study was Pro-Feme, a commercially available product manufactured by Lawley Pharmaceuticals. Participants applied 4 cm (equivalent to 32 mg) once daily to the skin, the manufacturer’s recommended dose for treating menopausal women.
  • OUTCOMES MEASURED: Investigators evaluated menopausal symptoms monthly using the Greene Climacteric Scale and, at the end of the study, the Menopause Specific Quality of Life Questionnaire (MENQOL). The Greene Climacteric Scale assesses 5 symptom areas (vasomotor, somatic, anxiety, depression, and sex response), and the MENQOL assesses 4 types of symptoms (vasomotor, physical, psychosocial, and sex-related). Higher scores indicate more severe symptoms on both instruments. The study also measured serum progesterone, lipid levels, and indices of bone metabolism.
  • RESULTS: Severity scores for menopausal symptoms appeared similar between groups at baseline, but statistical analysis was not reported. Investigators did not find a significant decrease in menopausal symptoms between progesterone and placebo based on the Greene Climacteric Scale or MENQOL. No differences were found in serum lipid levels or markers of bone metabolism. Serum progesterone significantly increased in the treatment group compared with placebo, but this increase did not induce a biological response in the endometrium.
PDF Download

 

PRACTICE RECOMMENDATIONS

Transdermal progesterone cream, at the dose used in this study, did not improve menopausal symptoms compared with placebo. The study, however, might not have been large enough to detect a difference if one really exists.

In light of recent safety concerns over the use of other types of hormone replacement therapy, treatment of menopausal symptoms with transdermal progesterone should not be used unless better information supporting its benefit becomes available.

Recommended Reading

Which postmenopausal women should be offered combined HRT?
MDedge Family Medicine
Does cranberry juice prevent or treat urinary tract infection?
MDedge Family Medicine
Do calcium supplements prevent postmenopausal osteoporotic fractures?
MDedge Family Medicine
Treating hot flushes without hormone replacement therapy
MDedge Family Medicine
Remote diagnosis of cervical neoplasia: 2 types of telecolposcopy compared with cervicography
MDedge Family Medicine
What nonhormonal therapies are effective for postmenopausal vasomotor symptoms?
MDedge Family Medicine
Is osteoporosis screening in postmenopausal women effective?
MDedge Family Medicine
Vaccine prevents genital herpes in subgroup of women
MDedge Family Medicine
Self-examination does not reduce breast cancer mortality
MDedge Family Medicine
Does C-reactive protein predict cardiovascular events in women better than LDL?
MDedge Family Medicine